Overview
Identifeye Health provides an AI-powered retinal imaging platform for healthcare providers to capture and analyze eye images in real time. The system uses a retinal imaging device or integration to collect images and an AI layer to identify biomarkers and risk indicators, with results shown in a clinician-facing interface for quick interpretation. It stands out by targeting point-of-care use by non-specialists and by offering ongoing AI algorithm updates and services to clinics and hospitals. The goal is to broaden access to accurate retinal assessments and enable earlier disease detection and better patient outcomes through streamlined workflows and real-time decision support.
Work here?Claim your company
Simplify's take
What believers are saying
- Commercial launch began in August 2025, establishing live U.S. distribution.
- The October 2026 white paper validates real-world diabetic retinopathy performance in undilated images.
- FDA device listing on October 26, 2026 confirms active manufacturing and distribution.
What critics are saying
- The U.S. AI Toolkit remains unavailable, blocking software monetization and clinician adoption.
- Simplify.jobs reported headcount fell 42.3% from 2023 to March 2026.
- If hospitals cannot reimburse screenings, device sales stall and 4Catalyzer subsidy becomes essential.
What makes identifeye HEALTH unique
- Identifeye sells FDA-registered retinal hardware plus portal, enabling non-specialists to screen patients.
- Its October 2026 RAM program delivered 446 exams and 98 referrals across four clinics.
- The company owns a point-of-care workflow, not just software, from capture to review.
Help us improve and share your feedback! Did you find this helpful?